Vanda Pharmaceuticals
VNDA
189 hedge funds and large institutions have $819M invested in Vanda Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 73 increasing their positions, 63 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
16% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 63
13% more capital invested
Capital invested by funds: $723M → $819M (+$96.6M)
6% more funds holding
Funds holding: 178 → 189 (+11)
1% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $1.82M
1.23% less ownership
Funds ownership: 100.71% → 99.48% (-1.2%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIP
Epoch Investment Partners
New York
|
+$18.8M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$15.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$5.54M |
| 4 |
BlackRock
New York
|
+$3.54M |
| 5 |
Citigroup
New York
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$26M |
| 2 |
Morgan Stanley
New York
|
-$10.2M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$7.1M |
| 4 |
Renaissance Technologies
New York
|
-$4.92M |
| 5 |
Man Group
London,
United Kingdom
|
-$4.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VCG
201
Vantage Consulting Group
Virginia Beach,
Virginia
| – | -$23K | -1,724 | Closed |
|
|
FTDI
202
First Trust Direct Indexing
Boston,
Massachusetts
| – | -$9K | -657 | Closed |
|
203
Rockefeller Capital Management
New York
| – | -$6K | -500 | Closed |
|
|
PWPS
204
Pinnacle Wealth Planning Services
Mansfield,
Ohio
| – | -$3K | -226 | Closed |
|
|
GLLW
205
Graves Light Lenhart Wealth
Harrisonburg,
Virginia
| – | -$3K | -200 | Closed |
|
VNDA Hedge Fund Activity: Q1 2021 in Review
189 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2021, worth a combined $819M — up 13% from $723M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new VNDA positions and 17 closed out — a net gain of 13 holders — while 73 added to existing stakes and 63 trimmed.
The largest buyer was Epoch Investment Partners, opening a new position worth an estimated $18.8M. The largest seller was Armistice Capital, cutting an estimated $26M.
- 189 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2021, up from 178 in Q4 2020.
- Funds reported $819M of Vanda Pharmaceuticals stock for Q1 2021, up 13% quarter-over-quarter.
- 30 funds opened new Vanda Pharmaceuticals positions in Q1 2021 and 17 closed out, a net change of +13 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2021 was Epoch Investment Partners, an estimated $18.8M added.
- The largest Vanda Pharmaceuticals seller in Q1 2021 was Armistice Capital, an estimated $26M sold.
Based on aggregated 13F filings for Q1 2021.